• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by HH&L Acquisition Co.

    1/31/24 6:09:49 AM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    SC 13G 1 d757518dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    HH&L Acquisition Co.

    G39714103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages

    Page 1 of 11 Pages

    Exhibit Index: 10 Page

     

     

     


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 2 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Harraden Circle Investments, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      201,825

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      201,825

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      201,825

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.80%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO, HC, IA


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 3 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Harraden Circle Investors GP, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      169,793

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      169,793

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      169,793

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.04%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN, HC


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 4 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Harraden Circle Investors GP, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      169,793

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      169,793

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      169,793

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.04%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO, HC


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 5 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Harraden Circle Investors, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      169,793

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      169,793

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      169,793

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.04%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 6 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Frederick V. Fortmiller, Jr.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      201,825

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      201,825

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      201,825

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.80%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN, HC


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 7 of 11 Pages

     

    Item 1(a).

    Name of Issuer

    HH&L Acquisition Co. (the “issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices

    Suite 2001-2002, 20/F, York House, The Landmark, 15 Queen’s Road Central, Central, Hong Kong

     

    Item 2(a).

    Names of Persons Filing

    This Statement is filed on behalf of the following persons (collectively, the “Reporting Persons”):

     

      i)

    Harraden Circle Investors, LP (“Harraden Fund”);

     

      ii)

    Harraden Circle Investors GP, LP (“Harraden GP”); Harraden

     

      iii)

    Circle Investors GP, LLC (“Harraden LLC”); Harraden Circle

     

      iv)

    Investments, LLC (“Harraden Adviser”); and Frederick V.

     

      v)

    Fortmiller, Jr. (“Mr. Fortmiller”);

    This Statement relates to Shares (as defined herein) directly beneficially owned by Harraden Fund. Harraden GP is the general partner to Harraden Fund, and Harraden LLC is the general partner of Harraden GP. Harraden Adviser serves as investment manager to Harraden Fund and other high net worth individuals. Mr. Fortmiller is the managing member of each of Harraden LLC and Harraden Adviser. In such capacities, each of Harraden GP, Harraden LLC, Harraden Adviser and Mr. Fortmiller may be deemed to indirectly beneficially own the Shares reported herein directly beneficially owned by Harraden Fund.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence

    The address of the principal business office of each Reporting Person is 299 Park Avenue, 21st Floor, New York, NY 10171.

     

    Item 2(c).

    Citizenship

    Each of Harraden Fund and Harraden GP is a Delaware limited partnership. Each of Harraden LLC and Harraden Adviser is a Delaware limited liability company. Mr. Fortmiller is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities

    Class A Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2(e).

    CUSIP No. G39714103

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    This Item 3 is not applicable.


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 8 of 11 Pages

     

    Item 4.

    Ownership

     

    Item 4(a)

    Amount Beneficially Owned

    As of December 31, 2023, each of the Reporting Persons may be deemed the beneficial owner of 201,825 Shares underlying Units held directly by Harraden

     

    Item 4(b)

    Percent of Class

    As of December 31, 2023, each of the Reporting Persons may be deemed the beneficial owner of approximately 4.80% of Shares outstanding. This percentage is based on a total of 4,205,185 Shares outstanding, based on information in the Form 10Q filed by the Company on November 20, 2023.

     

    Item 4(c)

    Number of shares as to which such person has:

     

    (i) Sole power to vote or direct the vote:

         0  

    (ii) Shared power to vote or direct the vote:

         201,825  

    (iii) Sole power to dispose or direct the disposition of:

         0  

    (iv) Shared power to dispose or direct the disposition of:

         201,825  

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    This Item 5 is not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    See disclosure in Item 2 hereof.

     

    Item 8.

    Identification and Classification of Members of the Group

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    This Item 9 is not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 9 of 11 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: January 31, 2024

     

    HARRADEN CIRCLE INVESTORS, LP
    By:   HARRADEN CIRCLE INVESTORS GP, LP, its general partner
    By:   HARRADEN CIRCLE INVESTORS GP, LLC, its general partner
    By:   /s/ Frederick V. Fortmiller, Jr.
    Title: Managing Member
    HARRADEN CIRCLE INVESTORS GP, LP
    By:   HARRADEN CIRCLE INVESTORS GP, LLC, its general partner
    By:   /s/ Frederick V. Fortmiller, Jr.
    Title: Managing Member
    HARRADEN CIRCLE INVESTORS GP, LLC
    By:   /s/ Frederick V. Fortmiller, Jr.
      Managing Member
    HARRADEN CIRCLE INVESTMENTS, LLC
    By:   /s/ Frederick V. Fortmiller, Jr.
      Managing Member
    FREDERICK V. FORTMILLER, JR.
    /s/ Frederick V. Fortmiller, Jr.


       SCHEDULE 13G   
    CUSIP No. G39714103       Page 10 of 11 Pages

     

    Exhibit INDEX

     

    Joint Filing Agreement    11
    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care